Eur J Endocrinol
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
 QUICK SEARCH:   [advanced]


     


Accepted Preprint first posted online on 5 March 2008

European Journal of Endocrinology 2008;158:817.

DOI: 10.1530/EJE-07-0649
Copyright © 2008 by European Society of Endocrinology
This Article
Right arrow Accepted manuscript (PDF)
Right arrow All Versions of this Article:
EJE-07-0649v1
158/6/817    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Hayashi, M.
Right arrow Articles by Komiya, I.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Hayashi, M.
Right arrow Articles by Komiya, I.

RESEARCH

Association of an A/C single nucleotide polymorphism in programmed cell death-ligand 1 (PD-L1) gene with Graves' disease in Japanese patients

Mina Hayashi, Tsuyoshi Kouki, Nobuyuki Takasu, Sumito Sunagawa and Ichiro Komiya

M Hayashi, Department of Endocrinology and Metabolism, University of the Ryukyus School of Medicine, Nishihara, Japan
T Kouki, Department of Endocrinology and Metabolism, University of the Ryukyus School of Medicine , Nishihara, 9030215, Japan
N Takasu, Department of Endocrinology and Metabolism, University of the Ryukyus School of Medicine, Nishihara, Japan
S Sunagawa, Department of Endocrinology and Metabolism, University of the Ryukyus School of Medicine, Nishihara, Japan
I Komiya, Department of Endocrinology and Metabolism, University of the Ryukyus School of Medicine, Nishihara, Japan

Correspondence: Tsuyoshi Kouki, Email: tkouki{at}ryudai2nai.com

Abstract

Objective: Programmed cell death-1 (PD-1) and its ligands (PD-L1 and PD-L2) inhibit T cell proliferation and activation. This inhibition down-regulates the immune responses. The association of a PD-L1-polymorphism with Graves' disease (GD) was studied.

Design: Association of an A/C polymorphism at position 8923 in PD-L1 with GD was studied.

Patients: 327 GD-patients and 192 controls were studied. 252 GD-patients were followed over 5-10 years.

Measurements: PD-L1 intron 4 position 8923 A/C polymorphism was typed using the PCR-restriction fragment length polymorphism method.

Results: The A/C genotype frequencies were significantly different between GD-patients and controls. The A/C and C/C frequencies were higher in GD-patients than in controls. The A/A frequency was lower in GD-patients than in controls. C-allele frequency was higher in GD-patients than in controls. 252 GD-patients were followed over 5-10 years; 200 had discontinued antithyroid drugs (ATD) while 52 continued to take ATD. Of these 200, 176 continued to be in remission and 24 had relapsed into hyperthyroidism. Significant differences in the duration of positive TBII, positive TSAb, and ATD-treatment were noted between the patients in remission and those that had relapsed. Significant differences in the A, C allele-frequencies were noted between the two. The C allele frequency was higher in GD-patients, who did not achieve remission, than in those, who achieved remission.

Conclusion: An A/C polymorphism at position 8923 in PD-L1 is associated with GD. The PD-L1 polymorphism plays a role in GD-development. GD-patients with the C allele at position 8923 in PD-L1 gene had difficulty in achieving remission.







HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
Copyright © 2008 European Society of Endocrinology.